Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Gerald Hsu

Lymphoma · UCSF

View

Dr. Chadi Nabhan

Lymphoma · Ryght AI / USC

View

Dr. Mark Roschewski

Lymphoma · MSK

View

Dr. Jonathan Friedberg

Lymphoma · URMC

View

Dr. Matthew Matasar

Lymphoma · Rutgers Cancer Institute

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    JC

    Dr. Julio Chavez

    Hematology & Oncology · Lymphoma
    Mayo Clinic in Florida
    julio

    Research

    Should CAR-T Cell Therapy be Considered a Standard of Care for Patients With Refractory Diffuse Large B-Cell Lymphoma in Second Line Treatment?

    2025

    Via Expert Opinion on Biological Therapy

    Research

    Outcomes of Patients With Richter Transformation Who Received No Prior Chemoimmunotherapy for Their CLL

    2025

    Via Blood Cancer Journal

    Research

    Chimeric Antigen Receptor T Cell Therapy in Octogenarians With B Cell Lymphoma

    2025

    Via Bone Marrow Transplantation

    Research

    Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies

    2025

    Via Targeted Oncology

    Research

    Sarcopenia and Skeletal Muscle Loss After CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma

    2025

    Via Clinical Cancer Research

    Research

    Evaluating the Role of CAR-T Cell Therapy in the Context of Current Therapy Options for Patients With Relapsed or Refractory Follicular Lymphoma

    2025

    Via Transplantation and Cellular Therapy

    Research

    Corrigendum to 'Clinical Practice Recommendations for Hematopoietic Cell Transplantation'

    2025

    Via Transplantation and Cellular Therapy

    Research

    Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era

    2025

    Via American Journal of Hematology

    Research

    Comparison of Axicabtagene Ciloleucel and Tisagenlecleucel Patient CAR-T Cell Products by Single-Cell RNA Sequencing

    2025

    Via Journal for Immunotherapy of Cancer

    Research

    Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

    2025

    Via Journal of Clinical Oncology

    Research

    Who Is Eligible for CAR T-Cell Therapy? Expert Perspectives on Overcoming Referral Barriers

    2025

    Via Transplantation and Cellular Therapy

    Research

    Three-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)

    2024

    Via Blood

    Research

    Bridging Therapy With Axicabtagene Ciloleucel for Large B-Cell Lymphoma

    2024

    Via Blood Advances

    Research

    Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-Cell Lymphoma

    2024

    Via Blood Cancer Discovery

    Research

    Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update

    2024

    Via Blood